Sophie Duraffour
Overview
Explore the profile of Sophie Duraffour including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
3477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Penfold S, Adegnika A, Asogun D, Ayodeji O, Azuogu B, Fischer 2nd W, et al.
PLoS One
. 2025 Jan;
20(1):e0317720.
PMID: 39808605
[This corrects the article DOI: 10.1371/journal.pone.0283643.].
2.
Watson C, Gsell P, Hall Y, Camacho A, Riveros X, Enwere G, et al.
BMC Med
. 2024 Nov;
22(1):523.
PMID: 39511527
Background: Zaire Ebolavirus disease (EVD) outbreaks can be controlled using rVSV-ZEBOV vaccination and other public health measures. People in high-risk areas may have pre-existing antibodies from asymptomatic Ebolavirus exposure that...
3.
Ogbaini-Emovon E, Akpede G, Okogbenin S, Osagiede E, Tobin E, Asogun D, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae575.
PMID: 39450398
Background: The standard of care for Lassa fever is the use of ribavirin with supportive therapy. There is little information on the course of viremia and its relationship with clinical...
4.
Duvignaud A, Etafo I, Jaspard M, Salau Q, Serra B, Kareem A, et al.
J Pediatric Infect Dis Soc
. 2024 Aug;
13(10):513-522.
PMID: 39167706
Background: Data on the presentation, management, and outcomes of Lassa fever (LF) in children are limited. Methods: Description of the clinical and biological features, treatment, and outcomes of reverse transcriptase...
5.
Kayem N, Okogbenin S, Okoeguale J, Momoh M, Njoku A, Eifediyi R, et al.
PLoS Negl Trop Dis
. 2023 May;
17(5):e0011354.
PMID: 37216412
Background: There is limited epidemiological evidence on Lassa fever in pregnant women with acute gaps on prevalence, infection incidence, and risk factors. Such evidence would facilitate the design of therapeutic...
6.
Kayem N, Okogbenin S, Okoeguale J, Eigbefoh J, Ikheloa J, Eifediyi R, et al.
PLoS Negl Trop Dis
. 2023 Apr;
17(4):e0011209.
PMID: 37053304
Background: Evidence from previous studies suggest that Lassa fever, a viral haemorrhagic fever endemic to West Africa has high case fatalities, particularly in pregnancy. While there have been remarkable innovations...
7.
Penfold S, Adegnika A, Asogun D, Ayodeji O, Azuogu B, Fischer 2nd W, et al.
PLoS One
. 2023 Mar;
18(3):e0283643.
PMID: 36996258
Background: Lassa fever (LF), a haemorrhagic illness caused by the Lassa fever virus (LASV), is endemic in West Africa and causes 5000 fatalities every year. The true prevalence and incidence...
8.
Gehre F, Lagu H, Achol E, Omari N, Ochido G, Duraffour S, et al.
BMJ Glob Health
. 2022 Dec;
7(12).
PMID: 36524412
No abstract available.
9.
Klitting R, Kafetzopoulou L, Thiery W, Dudas G, Gryseels S, Kotamarthi A, et al.
Nat Commun
. 2022 Sep;
13(1):5596.
PMID: 36167835
Lassa fever is a severe viral hemorrhagic fever caused by a zoonotic virus that repeatedly spills over to humans from its rodent reservoirs. It is currently not known how climate...
10.
Groger M, Akhideno P, Kleist C, Babatunde F, Edeawe O, Hinzmann J, et al.
Clin Infect Dis
. 2022 Jul;
76(3):e841-e848.
PMID: 35881530
Background: Lassa fever is endemic in large parts of West Africa. The recommended antiviral treatment is ribavirin. Two treatment regimens are currently endorsed in Nigeria: the "McCormick regimen" based on...